

XXth International Symposium on Medicinal Chemistry

EFMC-ISMC 2008

Vienna, Austria, August 31 - September 4, 2008

www.ismc2008.org

The **EFMC-ISMC 2008** Symposium is organized by the **Austrian Chemical Society** on behalf of the **European Federation for Medicinal Chemistry (EFMC)**.

This symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance, which varies between 1200 and 1500 participants from all over Europe, but also from the United States and Asia.

Welcome

The Organising Committee cordially invites you to attend the XXth International Symposium on Medicinal Chemistry that will be held in Vienna on August 31 to September 4, 2008, organised by the Austrian Chemical Society, on behalf of the European Federation for Medicinal Chemistry (EFMC).

The XXth ISMC will continue the tradition established by this biannual International Symposia covering drug discovery advances in all therapeutic areas as well as the most recent advances in lead identification strategies, drug design and profiling technologies. The emphasis will be on first time disclosures. The 2008 ISMC will also illustrate the impact of the "omics" area on the interfaces between chemistry, informatics and biology.

The Congress venue, Austria Center Vienna is located in the central area of Vienna and offers state of the art facilities for speakers, exhibitors and attendants.

Vienna, located in the very heart of Europe offers itself as the most sophisticated and distinguished venue for conventions. The climate of tolerance and understanding creates ideal conditions for international meetings. The City's active commitment to research, its prospering economy together with its rich cultural life, stimulating arts and music scene and its refined lifestyle will provide and enjoyable and valuable complement to a successful meeting.

Looking forward to your active participation!
Peter Ettmayer
Symposium Chairman

PRELIMINARY PROGRAMME (Please visit www.ismc2008.org for the detailed preliminary programme)

Confirmed Plenary Lecturers

Magid ABOU-GH ARBIA (Wyeth Research, USA)
Chris DOBSON (University of Cambridge, United Kingdom)
Paul HER LING (Novartis International, Switzerland)
Barbara IM PERI ALI (Massachusetts Institute of Technology, United States)
Steven V. LEY (University of Cambridge, United Kingdom)

Confirmed Key Lecturers

Jan BALZARINI (Rega Institute for Medical Research, Belgium)
Tesfaye BIFTU (Merck & Co., United States)
Jeff BLANE Y (Structural GenomiX, United States)
Arthur CHRI STOPOULOS (Monash University, Australia)
Andrew Mark DAVIS (AstraZeneca, United Kingdom)
George V. DE LUCCA (Bristol-Myers Squibb, United States)
Zahi A. FAYAD (Mount Sinai School of Medicine, United States)
Nobutaka FUJII (Kyoto University, Japan)
Giovanni GAVIR AGHI (Siena Biotech, Italy)
Gunda I. GE ORG (University of Minnesota, United States)
Kenneth A. JACOBSON (NI DDK, United States)

Stefan McDONOUGH (Amgen, United States)
Murray McKINN ON (Bristol-Myers Squibb, United States)
Isao NAKANI SHI (Kyoto University, Japan)
Tudor I. OPRE A (University of New Mexico, United States)
Leonard J. PAGLIARO (Biolmage, Denmark)
Dennis POWELL (Wyeth Research, United States)
David REE S (Astex Therapeutics, United Kingdom)
Gisbert SCHNEI DER (Johann Wolfgang Goethe University, Germany)
Klaus SIM ONSSEN (H. Lundbeck, Denmark)
Hans WESTERH OFF (VU University Amsterdam, The Netherlands)
Edward ZART LER (Merck, United States)

Confirmed Lecturers

Jeffrey ALBERT (AstraZeneca, United States)
Alexander ALEX (Pfizer, United Kingdom)
Pier Giovanni BARALDI (University of Ferrara, Italy)
Gianni CESARENI (University of Rome 'Tor Vergata', Italy)
Christopher COX (Merck Research Laboratories, United States)
Esteban DOMING O (Universidad Autonoma de Madrid, Spain)
Joseph L. DUFFY (Merck Research Laboratories, United States)
Carlos GARCIA-ECHE VERRI A (Novartis, Switzerland)
Elisabet GREG ORI -PUIG JANE (Chemotargets, Spain)
Jérôme GUILLEM ONT (Johnson & Johnson PRD, Belgium)
George HARTM ANN (Merck Research Laboratories, United States)
Dirk HEER DING (GlaxoSmithKline, United States)
Ilkka HEMI LA (PerkinElmer Life Sciences, Finland)
Matthias HOFFMANN (Boehringer Ingelheim, Germany)
Roderick E. HUBBARD (University of York, United Kingdom)
Ad P. IJZERMAN (Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands)
Steve JACOBSEN (Wyeth Research, United States)
Christopher N. JOHN SON (GlaxoSmithKline, United Kingdom)
Lucienne JUILLER AT (CHUV, Switzerland)
Muthukumarasamy KARTHI KEYAN (National Chemical Laboratory, Pune, India)
Philipp KRASTE L (Novartis, Switzerland)
Hilal A. LASHUEL (EPFL, Switzerland)
Jesper LAU (Novo Nordisk, Denmark)
Louis LOMBARDO (Bristol-Myers Squibb, United States)
Antonio MACCHI ARULO (University of Perugia, Italy)
Graham N. MAW (Pfizer, United Kingdom)
Jordi ME STRE S (IMIM and Universitat Pompeu Fabra, Spain)
Wolfgang MI LTZ (Novartis Pharma, Switzerland)
Christian NOE (University of Vienna, Austria)
Hartmut REH WIN KEL (Schering, Germany)
Jean-Louis RE YMOND (Universität Bern, Switzerland)
Susanne ROEHRIG (Bayer Healthcare, Germany)
Thomas RÜCKLE (Merck Serono, Switzerland)
Ronit SATCHI -FAIR ANO (Tel Aviv University, Israel)
Thomas J. SCHALL (Chemocentryx, United States)
Ansgar SCHUFFENH AUER (Novartis Institutes for Biomedical Research, Switzerland)
Peter SCHULZ-KNAPPE (Proteome Sciences, United Kingdom)
Andrew TH OMAS (AstraZeneca, United Kingdom)
Jose VARGHE SE (CSIR O, Australia)
Patrick Robert VERH OEST (Pfizer Global Research, United States)
Harel WEIN STEIN (Cornell University, United States)
Stefan WET ZEL (Max Planck Institute of Molecular Physiology, Germany)

Organising Committee

Chairman
Peter ETM AYER (Boehringer Ingelheim, Austria)
Members
Gerhard ECKER (University of Vienna, Austria & EFMC)
Roberto PELLICCIARI (University of Perugia, Italy & EFMC)
Ferran SANZ (Universitat Pompeu Fabra, Spain)
Edmond DIFFER DING (UCB, Belgium)

International Scientific Committee

M. ABOU-GH ARBIA (Wyeth Research, United States)

D. ALKER (David Alker Associates, United Kingdom)
K. AUGUSTYNS (University of Antwerp, Belgium)
S O. BACHURIN (Institute of Physiologically Active Compounds, Russia)
E. BANOGLU (Gazi University, Turkey)
P G. BARALDI (University of Ferrara, Italy)
K P. BØGE SO (H. Lundbeck, Denmark)
S. BOYER (AstraZeneca, Sweden)
H. BRAUNER -OSBORNE (The Danish University of Pharmaceutical Sciences, Denmark)
A. CAROTTI (University of Bari, Italy)
N. CARR UTHER S (Johnson & Johnson R&D, United States)
B. COX (Novartis Institutes for Biomedical Research, United Kingdom)
A J. DOMB (Hebrew University of Jerusalem, Israel)
G. DUBURS (Latvian Institute of Microbiology and Biotechnology, Latvia)
M. DUGGAN (Amgen, United States)
J. FISCHER (Richter, Hungary)
G. FOLKER S (Collegium Helveticum, Switzerland)
R. GANE LLIN (University College London, United Kingdom)
G. GAVIR AGHI (Siena Biotech, Italy)
P. GE ORGE (Sanofi-Aventis, France)
M P. GOYA LAZA (Universidad Complutense de Madrid, Spain)
S. GR OSSMAN (Bristol-Myers Squibb, United States)
G. GUILLAUMET (Université d'Orléans, France)
E. HAAKSMA (Boehringer Ingelheim, Austria)
K A. JACOBSON (NI DDK, United States)
A. KARLÉN (Uppsala University, Sweden)
J. KAROLAK-WOJCIE CHOWSKA (Technical University Lodz, Poland)
K. KIE C-KONONOWICZ (Jagiellonian University, Poland)
D. KIKELJ (University of Ljubljana, Slovenia)
A. KOZIKOWSKI (University of Illinois, United States)
P. KROGSGAARD-LARSEN (The Carlsberg Foundation, Denmark)
P. LEE SON (AstraZeneca, United Kingdom)
B. LESUR (Institut de Recherches Servier, France)
R. LEURS (VU University Amsterdam, The Netherlands)
M L. LÓPEZ-RODRIG UEZ (Universidad Complutense Madrid, Spain)
P. MÁTYUS (Semmelweis University, Hungary)
R. METERNI CH (Merck, United States)
D. MI DDLET ON (Pfizer, United Kingdom)
P. MOHR (F. Hoffmann-La Roche, Switzerland)
J. MULZER (University of Vienna, Austria)
P. NANTERMET (Merck, United States)
C. NOE (University of Vienna, Austria)
P. NUSSBAUMER (Novartis, Austria)
L. PARDO (Universitat Autònoma de Barcelona, Spain)
P S. PORT OGHE SE (University of Minnesota, United States)
D. ROGN AN (Université Louis Pasteur, France)
G. RONSISVALLE (Università Degli Studi di Catania, Italy)
D. ROTE LLA (Wyeth Research, United States)
F. SAHIN (Gazi University, Turkey)
G. SCHN ORREN BERG (Boehringer Ingelheim, Germany)
G. STEM P (GlaxoSmithKline, United Kingdom)
H-U. STI LZ (Sanofi-Aventis, Germany)
H. TIMERM AN (VU University Amsterdam, The Netherlands)
A. TSANTI LI-KAKOULIDOU (University of Athens, Greece)
S. VAN BOECKEL (Organon, The Netherlands)
H. WALDMANN (Max Planck Institute of Molecular Physiology, Germany)
N S. ZEFIR OV (Moscow State University, Russia)

EFMC-ISMC 2008 Symposium Secretariat:

LD Organisation, Scientific Conference Producers
55, route de Blocry,
B-1348 Louvain-la-Neuve, Belgium
Tel.: +32 10 45 47 77 - Fax: +32 10 45 97 19
secretariat@ISM2008.org

www.ismc2008.org